Is it safe to use Dayvigo (lemborexant) together with Xulane (ethinyl estradiol 20 µg/norelgestromin 150 µg transdermal patch), and what are the appropriate dosing schedules and safety considerations for both medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Xulane and Dayvigo Can Be Used Together Safely Without Dose Adjustment

Based on direct drug interaction study data, lemborexant (Dayvigo) and combined hormonal contraceptives like Xulane can be coadministered without dose adjustment, as lemborexant has no clinically relevant effect on contraceptive hormone levels 1.

Drug Interaction Profile

A dedicated phase 1 drug-drug interaction study specifically examined lemborexant 10 mg with an oral contraceptive containing ethinyl estradiol and norethindrone acetate (similar hormones to Xulane's ethinyl estradiol/norelgestromin). The study found 1:

  • Ethinyl estradiol exposure increased by only 13% (area under the curve), which is not clinically significant
  • No clinically relevant effects on progestin pharmacokinetics were observed
  • Contraceptive efficacy is maintained when used with lemborexant
  • No dose adjustment needed for either medication

While this study used an oral contraceptive, the hormones are essentially identical to those in Xulane (ethinyl estradiol is the same; norelgestromin is the active metabolite of norethindrone), making these findings directly applicable.

Dosing Schedules

Xulane (Contraceptive Patch)

  • Apply one patch weekly for 3 consecutive weeks, followed by 1 patch-free week 2
  • Each patch releases 150 µg norelgestromin and 20 µg ethinyl estradiol daily 2
  • Can be applied to abdomen, buttock, upper outer arm, or upper torso (excluding breasts)
  • Change on the same day each week

Dayvigo (Lemborexant)

  • Start with 5 mg taken once nightly, immediately before bed 3
  • Must have at least 7 hours remaining before planned awakening 3
  • May increase to maximum 10 mg based on clinical response 3
  • Take on an empty stomach or light meal - time to sleep onset is delayed if taken with or soon after a meal 3

Critical Safety Considerations

CNS Depression Risk

The primary concern is additive CNS depressant effects, not a pharmacokinetic interaction 3. Dayvigo causes:

  • Somnolence (10% at 10 mg dose, 7% at 5 mg dose) 3
  • Next-day impairment that can persist for several days after discontinuation 3
  • Increased fall risk, particularly in elderly patients 3

Avoid alcohol completely when using Dayvigo, as coadministration produces greater negative impacts on postural stability and memory 3.

Unique Dayvigo Side Effects to Monitor

  • Sleep paralysis (1.6% at 10 mg, 1.3% at 5 mg) 3
  • Hypnagogic/hypnopompic hallucinations (0.7% at 10 mg) 3
  • Cataplexy-like symptoms (leg weakness lasting seconds to minutes) 3
  • Complex sleep behaviors (rare but reported) 3

Xulane-Specific Considerations

  • Higher estrogen exposure than oral contraceptives (1.6 times higher) 4
  • Possible increased VTE risk compared to 20-35 µg oral contraceptives (odds ratios 1.2-2.2) 4
  • Application site reactions unique to the patch 5
  • Patch adhesion is reliable even with exercise, water immersion, and humid climates 6, 7, 8

Contraceptive Effectiveness Maintained

If patch detachment or delayed application occurs 2:

For <48 hours delayed:

  • Apply new patch immediately
  • Keep same patch change day
  • No backup contraception needed

For ≥48 hours delayed:

  • Apply new patch immediately
  • Use backup contraception (condoms) for 7 consecutive days
  • If occurred in week 3: skip hormone-free week and start new patch immediately
  • Consider emergency contraception if occurred in week 1 with unprotected intercourse in previous 5 days

Drug Metabolism Considerations

Dayvigo is metabolized primarily by CYP3A 3, 9:

  • Avoid strong/moderate CYP3A inhibitors (itraconazole, clarithromycin, fluconazole, verapamil) 3
  • Maximum 5 mg dose with weak CYP3A inhibitors 3
  • Avoid strong/moderate CYP3A inducers (rifampin, carbamazepine, St. John's wort) 3

Dayvigo decreases CYP2B6 substrate levels - monitor efficacy of medications like bupropion or methadone if used concurrently 3.

Special Populations

Hepatic impairment:

  • Maximum 5 mg dose in moderate hepatic impairment 3
  • Not recommended in severe hepatic impairment 3

No dose adjustment needed for:

  • Age, sex, or race 10
  • Renal impairment (not specifically contraindicated) 3

Common Pitfalls to Avoid

  1. Taking Dayvigo with a large meal - delays absorption and sleep onset 3
  2. Not allowing 7 hours for sleep - increases next-day impairment risk 3
  3. Combining with alcohol - significantly increases CNS depression 3
  4. Starting at 10 mg dose - begin at 5 mg to assess tolerance 3
  5. Assuming patch failure affects contraceptive efficacy - Dayvigo does not compromise contraceptive hormone levels 1

References

Guideline

contraception for adolescents.

Pediatrics, 2014

Research

Pharmacokinetic overview of Ortho Evra/Evra.

Fertility and sterility, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.